Newsletter 1st Edition, 2023



Welcome to the first edition of the Paratus Clinical newsletter for 2023. At the end of 2022 we came together as a company to revise our company values. This was a collaborative effort in which every staff member had input. We are proud to share our current PARATUS CLINICAL VALUES with you....

COLLABORATION

We work in synergy with our participants, clients and each other allowing equal voice to achieve excellence

RESPECT & RESPONSIBILITY We understand our responsibilities and have the utmost respect for our internal and external stakeholders. We especially respect our amazing volunteer participants

QUALITY & SAFETY We pursue excellence to become an industry leader and prioritise participant safety

RESILIENCE

As a team, having the resilience and collective strength to pivot and adapt to the ever-changing environment of clinical research, is our greatest asset

The PARATUS CLINICAL VISION:

"To be the preferred provider for primary care clinical trials in Australasia"

The PARATUS CLINICAL MISSION:

"To significantly increase the opportunities in primary care settings for Australians to safely access novel treatments and contribute to furthering of clinical knowledge leading to better health outcomes for all"

Introducing our Commercial Lead

Heenal Patel, who some of you may know from the Western Sydney clinic as a Study Coordinator, was recently appointed to a new position as our Commercial Lead. Heenal brings a wide range of knowledge across multiple therapeutic areas and will be responsible for all feasibility and capability work. The role will include communications on site identification, client relations and contract & budget negotiations. She will be working closely with Matt Clacy, Chief Commercial Officer. Please reach out and connect with Heenal via LinkedIn at

https://www.linkedin.com/in/heenalpatel8 in



The value of pre-feasibility

Our Medical Directors/Principal Investigators are available to provide the site perspective on study and protocol design. This is a FREE consultation with your protocol developers that has proven to be invaluable. We will provide Australian specific medical advice including standard of care, specialist input and consider the trial design from a patient perspective. You will need to invest in a 1-2 hour call at the protocol design stage which in our experience has added the following

value:



If this pre-feasibility discussion is of interest to you, please contact matt.clacy@paratusclinical.com



An interview with Dr Leah

DR AMBER LEAH

Medical Director & Principal Investigator

What appealed to you about becoming a principal investigator and working in clinical research?

Working as a Principal Investigator allows me to combine both my medical and scientific backgrounds. I enjoy the day-to-day work and seeing participants as well as the more academic side of research reviewing clinical and published data. I am also fortunate to be involved in review of early study development including reviewing draft protocols. As an Investigator I have had the opportunity to give direct feedback to sponsors on their study and protocol design, this early communication allows greater understanding between sites and sponsors and helps avoid early pitfalls in study start up.

What are the types of trials you have worked on and do you have a favourite one or memorable moment?

To date I have worked on over 30 clinical trials with Paratus, I enjoy both high recruiting fast paced studies, such as some of our vaccine studies, as well as our longer more complex treatment trials. Last year I was able to present some of the important work we do at Paratus at ARCS, with a session on participant empowerment in clinical trials, an area of research that is very important to me.

Where do you see Paratus Clinical heading in the next 2-5 years?

The future of Paratus and clinical trials in Australia is optimistic, there are significant incentives, fast start up processes, a skilled workforce, and a population keen on being involved in clinical research.

Where do you see the future of clinical research heading?

I think the hard work and high quality of Paratus will continue to be recognised and we continue to become a preferred provider in the clinical trial space.



